Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
A phase 2 trial of Decitabine, Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. is a phase 2 interventional study registered as NCT05201066 by Novartis Pharmaceuticals, with 33 participants enrolled, started 2023-02-28 and due to reach its primary completion in 2028-02-14. Interventions recorded: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax and INQOVI (oral decitabine).
Similar pages
not linked directly; found by shared links- TrialA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Shares Decitabine, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Decitabine, Azacitidine, Venetoclax and the tag pipeline.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Shares Azacitidine, Venetoclax and the tag pipeline.